A company called Quoin Pharmaceuticals did really well because they said their new medicine works better than people thought, so their shares became more valuable. Another company called Renalytix got a lot of attention after someone wanted to buy them, so their shares also went up. But some other companies had bad news or didn't do as well, so their shares went down in value. Oil and gold prices changed too. In different parts of the world, some places where people buy and sell things did better than others. Read from source...

1. The title of the article is misleading and sensationalized. It implies that crude oil prices are down significantly (over 1%) when in fact they only dropped by a modest amount (1.5%). This creates a false impression of volatility and uncertainty in the market, which may not be justified by the actual data.
2. The article focuses heavily on individual stock performances, but does not provide enough context or analysis to explain why these changes are happening. For example, it mentions that Quoin Pharmaceuticals shares spiked after reporting better-than-expected financial results and providing clinical updates, but it does not mention how these results compare to analyst expectations or industry standards. It also does not discuss the potential risks or challenges that these companies may face in the future, which could affect their stock prices.
3. The article uses vague and subjective terms to describe market trends, such as "European shares closed mostly lower today" or "Asian markets closed higher on Monday". These phrases do not provide any concrete information about the direction or magnitude of price movements, and may be interpreted differently by different readers. A more objective and precise way of reporting these trends would be to provide specific numbers or percentages, such as "European shares fell by 0.12% on average" or "Asian markets gained 1.5% collectively".
4. The article includes irrelevant information that does not directly relate to the topic at hand, such as the number of people registering as jobless in Spain or the bankruptcy filing of JOANN Inc. These details may be interesting or newsworthy on their own, but they do not contribute to a clear and coherent analysis of the market performance. They may also distract the reader from more important factors that affect the prices of oil, gold, silver, copper, and other commodities.

The article provides a mix of positive and negative news for various stocks, as well as some general market trends. Based on this information, I will provide you with my comprehensive investment recommendations and the associated risks. First, I would suggest investing in Renalytix Plc, which has received an unsolicited approach from a strategic diagnostics company. This indicates potential interest and value creation for the company's shares. However, there is also some risk involved, as the company operates in a competitive industry and may face regulatory hurdles or delays in executing its strategy. Second, I would recommend investing in Quoin Pharmaceuticals, Ltd., which has announced FDA clearance to recruit teen subjects into both of its ongoing Netherton Syndrome clinical studies. This is a positive development for the company and its shareholders, as it could lead to faster drug approvals and increased market demand. However, there are also risks involved, such as potential safety concerns or regulatory setbacks that may affect the company's performance and stock price. Third, I would suggest investing in BioVie Inc., which has reported pricing of a public offering. This could provide the company with additional capital to fund its operations and research & development activities. However, there is also some risk involved, as the company may face dilution of its shareholders' ownership and potential market pressure on its stock price.